RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q2 FY21 results · Jul–Sep 2020
RPG Life Sciences reported revenue from operations of ₹97.13 crore (down 1.4% from Q2 FY20) and net profit of ₹11.15 crore (up 14.1% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a standalone basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 97.13 | 98.49 | −1.4% | 91.65 | +6.0% |
| Other income | 0.04 | 0.15 | −73.3% | 0.45 | −91.1% |
| Total income | 97.17 | 98.64 | −1.5% | 92.10 | +5.5% |
| Profit before tax | 14.73 | 12.04 | +22.3% | 12.83 | +14.8% |
| Net profit for the period | 11.15 | 9.77 | +14.1% | 9.06 | +23.1% |
| EPS, basic (₹) | 6.74 | 5.91 | +14.0% | 5.48 | +23.0% |
| Net margin (%) | 11.5 | 9.9 | 9.9 |
Standalone
- Filed with BSE
- 06 Nov 2020, 13:18 IST
- Board meeting
- 30 Oct 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE